Dysregulation of HSG triggers vascular proliferative disorders
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Vascular proliferative disorders, such as atherosclerosis and restenosis, are the most common causes of severe cardiovascular diseases, but a common molecular mechanism remains elusive. Here, we identify and characterize a novel hyperplasia suppressor gene, named HSG (later re-named rat mitofusin-2). HSG expression was markedly reduced in hyper-proliferative vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rat arteries, balloon-injured Wistar Kyoto rat arteries, or ApoE-knockout mouse atherosclerotic arteries. Overexpression of HSG overtly suppressed serum-evoked VSMC proliferation in culture, and blocked balloon injury induced neointimal VSMC proliferation and restenosis in rat carotid arteries. The HSG anti-proliferative effect was mediated by inhibition of ERK/MAPK signalling and subsequent cell-cycle arrest. Deletion of the p21(ras) signature motif, but not the mitochondrial targeting domain, abolished HSG-induced growth arrest, indicating that rHSG-induced anti-proliferation was independent of mitochondrial fusion. Thus, rHSG functions as a cell proliferation suppressor, whereas dysregulation of rHSG results in proliferative disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides its role in mitochondrial fusion, Mfn2 has been described to be involved in the regulation of cell proliferation, oxidative metabolism, autophagy, mitophagy, mitochondrial antiviral signaling, and unfolded protein response (Bach et al, 2003; Chen et al, 2004; Yasukawa et al, 2009; Hailey et al, 2010; Ngoh et al, 2012; Zhao et al, 2012; Chen & Dorn, 2013; Munoz et al, 2013).”
From Mfn2 deficiency links age‐related sarcopenia and impaired autophagy to activation of an adaptive mitophagy pathway (2016) · cites this paper as Chen et al, 2004
In the citing paper
“Recently, it has been reported that Mfn2 binds Ras and its overexpression inhibits extracellular signalrelated kinase/mitogen-activated protein kinase signaling and subsequently arrests cell cycle (30).”
From Expression of Mfn2, the Charcot-Marie-Tooth Neuropathy Type 2A Gene, in Human Skeletal Muscle (2005) · cites this paper as [30]
Citations
Cites
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224 · cited 1×
“Recent studies indicate that coated stents with anti-proliferative agents, including rapamyci”
BackgroundMarshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“The Ras proto-oncogene is a central component of mitogenic signalling pathways, and is essential for cells to exit a quiescent state (G0) and to pass through the G1–S transition of the cell cycl”
BackgroundChen, H., Detmer, S. A., Ewald, A. J., Griffin, E. E., Fraser, S. E., & Chan, D. C. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200211046 · Cited by 2,601 · cited 1×
“Several studies have demonstrated that human Mfn-2 and its homologues localize to the mitochondrial outer membrane and have an essential role in mitochondrial fusion, thus regulating mitochondrial morphology and function in mammalian cells, yeast and flie”
BackgroundDevelopment of a Strain of Spontaneously Hypertensive Rats
OKAMOTO, K., & AOKI, K. (1963) · Japanese Circulation Journal · doi:10.1253/jcj.27.282 · Cited by 2,545
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., & Nakayama, K.-I. (1996) · Cell · doi:10.1016/s0092-8674(00)81237-4 · Cited by 1,547
Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L.-H., Broudy, V., Perlmutter, R. M., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81239-8 · Cited by 1,457
Tunstall-Pedoe, H., Kuulasmaa, K., Mähönen, M., Tolonen, H., & Ruokokoski, E. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04021-0 · Cited by 1,444
Clowes, A. W., Reidy, M. A., & Clowes, M. M. (1983) · PubMed · Cited by 1,437
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211 · cited 1×
“In fact, the anti-proliferative effect of human HSG is more potent than that induced by overexpression of p53, a well established tumour suppresso”
Background
Cited by
Mitofusin 2 tethers endoplasmic reticulum to mitochondria
de Brito, O. M., & Scorrano, L. (2008) · Nature · doi:10.1038/nature07534 · Cited by 2,442
Mitochondria: More Than Just a Powerhouse
McBride, H. M., Neuspiel, M., & Wasiak, S. (2006) · Current Biology · doi:10.1016/j.cub.2006.06.054 · Cited by 1,985
Mitochondrial dynamics and apoptosis
Suen, D.-F., Norris, K. L., & Youle, R. J. (2008) · Genes & Development · doi:10.1101/gad.1658508 · Cited by 1,270
Mitochondrial Dynamics — Mitochondrial Fission and Fusion in Human Diseases
Archer, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215233 · Cited by 1,102
Mitochondrial Dynamics in Mammalian Health and Disease
Liesa, M., Palacín, M., & Zorzano, A. (2009) · Physiological Reviews · doi:10.1152/physrev.00030.2008 · Cited by 953
“Mfn2 (named in the original study as “hyperplasia suppressor gene”, HSG) is repressed in VSMCs under conditions of hyperproliferative states such as atherosclerosis or restenosis (53).”
BackgroundInfluentialSebastián, D., Hernández-Alvarez, M. I., Segalés, J., Sorianello, E., Muñoz, J. P., Sala, D., Waget, A., Liesa, M., Paz, J. C., Gopalacharyulu, P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108220109 · Cited by 673
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer
Rehman, J., Zhang, H. J., Toth, P. T., Zhang, Y., Marsboom, G., Hong, Z., Salgia, R., Husain, A. N., Wietholt, C., & Archer, S. L. (2012) · The FASEB Journal · doi:10.1096/fj.11-196543 · Cited by 595
“sion can limit cell proliferation in vascular cells (29) or”
BackgroundMitochondrial-nuclear communications
Ryan, M. T., & Hoogenraad, N. J. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.052305.091720 · Cited by 575
Endoplasmic Reticulum and the Unfolded Protein Response
(2013) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-407704-1.00005-1 · Cited by 548
“Moreover, loss-offunction mutations of some proteins localized in MAMs promote cell proliferation and desensitize cells to apoptotic stimuli (Chen et al., 2004; Simmen et al., 2005; Hayashi and Su, 2007).”
BackgroundEmerging functions of mammalian mitochondrial fusion and fission
Chen, H., & Chan, D. C. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi270 · Cited by 538
“Mfn2 was identified as a hypertension-suppressor gene by differential display (60).”
BackgroundThe role of mitochondrial dysfunction in cardiovascular disease: a brief review
Chistiakov, D. A., Shkurat, T. P., Melnichenko, A. A., Grechko, A. V., & Orekhov, A. N. (2018) · Annals of Medicine · doi:10.1080/07853890.2017.1417631 · Cited by 495
Mitofusins, from Mitochondria to Metabolism
Schrepfer, E., & Scorrano, L. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.022 · Cited by 495
Pich, S., Bach, D., Briones, P., Liesa, M., Camps, M., Testar, X., Palacín, M., & Zorzano, A. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi149 · Cited by 455
“Mfn2 has been reported to operate as a cell proliferation suppressor both in vivo and in vitro by cell-cycle arrest in the G0/G1 phases (13).”
BackgroundBaloh, R. H., Schmidt, R. E., Pestronk, A., & Milbrandt, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4798-06.2007 · Cited by 451
“MFN2 is a dynamin family GTPase believed to primarily be involved in mitochondrial fusion, although it has also been implicated in regulating mitochondrial oxidative function (Pich et al., 2005), and intracellular signaling (Chen et al., 2004).”
BackgroundPGC-1α as a Pivotal Factor in Lipid and Metabolic Regulation
Cheng, C.-F., Ku, H.-C., & Lin, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113447 · Cited by 437
“However, Mfn2 is also known to suppress cell proliferative effects via p21Ras, independently of mitochondrial dynamics [152,153].”
BackgroundMitochondrial Regulation of Cell Cycle and Proliferation
Antico Arciuch, V. G., Elguero, M. E., Poderoso, J. J., & Carreras, M. C. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4085 · Cited by 434
“Mfns has also been shown to inhibit the ERK/MAPK signaling pathway (40).”
The Mitochondrial Basis of Aging and Age-Related Disorders
Srivastava, S. (2017) · Genes · doi:10.3390/genes8120398 · Cited by 420
Sebastián, D., Sorianello, E., Segalés, J., Irazoki, A., Ruiz‐Bonilla, V., Sala, D., Planet, E., Berenguer‐Llergo, A., Muñoz, J. P., Sánchez‐Feutrie, M., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201593084 · Cited by 396
“…of cell proliferation, oxidative metabolism, autophagy, mitophagy, mitochondrial antiviral signaling, and unfolded protein response (Bach et al , 2003; Chen et al , 2004; Yasukawa et al , 2009; Hailey et al , 2010; Ngoh et al , 2012; Zhao et al , 2012; Chen & Dorn, 2013; Munoz et al , 2013).”
Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology
Zhan, M., Brooks, C., Liu, F., Sun, L., & Dong, Z. (2013) · Kidney International · doi:10.1038/ki.2012.441 · Cited by 397
Wang, Q., Zhang, M., Torres, G., Wu, S., Ouyang, C., Xie, Z., & Zou, M.-H. (2017) · Diabetes · doi:10.2337/db16-0915 · Cited by 370
“Similarly, fish oil is an AMPK activator that regulates the expression of mitochondrial dynamics–related proteins, including mitofusin 2 (MFN2) and Fis1, accompanied with a reduction in atherosclerotic plaques in ApoE2/2 mice fed a high-fat diet (23).”
BackgroundInfluentialExpression of Mfn2, the Charcot-Marie-Tooth Neuropathy Type 2A Gene, in Human Skeletal Muscle
Bach, D., Naon, D., Pich, S., Soriano, F. X., Vega, N., Rieusset, J., Laville, M., Guillet, C., Boirie, Y., Wallberg-Henriksson, H., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2685 · Cited by 369
Archer, S. L., Gomberg-Maitland, M., Maitland, M. L., Rich, S., Garcia, J. G. N., & Weir, E. K. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01324.2007 · Cited by 366
“Mitofusin-2 not only controls mitochondrial form and function (20, 28, 36, 43, 65, 81– 83) but also regulates SMC proliferation (27, 28).”
BackgroundSoriano, F. X., Liesa, M., Bach, D., Chan, D. C., Palacín, M., & Zorzano, A. (2006) · Diabetes · doi:10.2337/db05-0509 · Cited by 343
“Based on the reported biological roles of Mfn2 (17,18,21,32,34), we also propose that PGC-1 may regulate mitochondrial fusion/ fission events and cell proliferation in cells.”
BackgroundLeboucher, G. P., Tsai, Y. C., Yang, M., Shaw, K. C., Zhou, M., Veenstra, T. D., Glickman, M. H., & Weissman, A. M. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.041 · Cited by 334
“These include roles in sequestering p21Ras (Chen et al., 2004), maintaining the mitochondrial electrochemical gradient (Pich et al.”
BackgroundMitochondrial morphology and cardiovascular disease
Ong, S.-B., & Hausenloy, D. J. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq237 · Cited by 323
“Chen et al.89 have shown in the cardiac myogenic H9c2 cell line that ischaemia-induced mitochondrial fragmentation was associated with a reduction in protein levels of the mitochondrial fusion protein, OPA1.”
BackgroundInfluentialThe Metabolic Theory of Pulmonary Arterial Hypertension
Paulin, R., & Michelakis, E. D. (2014) · Circulation Research · doi:10.1161/circresaha.115.301130 · Cited by 314
Neuspiel, M., Zunino, R., Gangaraju, S., Rippstein, P., & McBride, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501599200 · Cited by 306
Molecular Strategies for Targeting Antioxidants to Mitochondria: Therapeutic Implications
Apostolova, N., & Victor, V. M. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5952 · Cited by 299
“Furthermore, it has been proposed that Mfn2 correlates with the proliferation of vascular smooth muscle cells (42) and with the oxidative metabolism in muscle (16).”
Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 294
Hall, A. R., Burke, N., Dongworth, R. K., & Hausenloy, D. J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12516 · Cited by 283
“These vasculo-proliferative effects appeared to be mediated by inducing apoptotic death of VSMCs through the suppression of the Ras-Raf-MAPK-Erk1/2 and PI3K-Akt signalling pathways (Chen et al., 2004; Guo et al., 2007).”
Mitochondrial Dynamics: Coupling Mitochondrial Fitness with Healthy Aging
Sebastián, D., Palacín, M., & Zorzano, A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.003 · Cited by 282
“Indeed, MFN2 was originally termed ‘Hyperplasia Suppressor Gene’ (HSG) because its dysregulation was initially discovered to trigger vascular proliferative disorders, such as atherosclerosis and restenosis [17].”
BackgroundInfluentialMitofusin 2 Inhibits Mitochondrial Antiviral Signaling
Yasukawa, K., Oshiumi, H., Takeda, M., Ishihara, N., Yanagi, Y., Seya, T., Kawabata, S.-I., & Koshiba, T. (2009) · Science Signaling · doi:10.1126/scisignal.2000287 · Cited by 255
Structure, function, and regulation of mitofusin‐2 in health and disease
Chandhok, G., Lazarou, M., & Neumann, B. (2018) · Biological Reviews · doi:10.1111/brv.12378 · Cited by 247
“Reduced Mfn2 levels are observed in spontaneously hypertensive or atherosclerosis-prone rat VSMCs (Chen et al., 2004), whereas Mfn2 overexpression decreases VSMC proliferation and sensitizes cells to H2O2-induced apoptosis (Guo et al., 2005, 2007).”
BackgroundInfluentialReciprocal Regulation of Mitochondrial Fission and Fusion
Sabouny, R., & Shutt, T. E. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.03.009 · Cited by 241
Mitochondrial dynamics and their potential as a therapeutic target
Whitley, B. N., Engelhart, E. A., & Hoppins, S. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.06.002 · Cited by 226
Makino, A., Scott, B. T., & Dillmann, W. H. (2010) · Diabetologia · doi:10.1007/s00125-010-1770-4 · Cited by 223
“In addition, MFN2 was identified as a suppressor of obesity [27, 28] and hypertension [25].”
The role of mitochondrial dynamics in cardiovascular diseases
Forte, M., Schirone, L., Ameri, P., Basso, C., Catalucci, D., Modica, J., Chimenti, C., Crotti, L., Frati, G., Rubattu, S., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15068 · Cited by 216
“Mfn2 expression was found to be reduced in thrombi harvested from animal models of atherosclerosis and humans (Chen et al., 2004; Liu et al., 2014).”
BackgroundCentral Role of Mitofusin 2 in Autophagosome-Lysosome Fusion in Cardiomyocytes
Zhao, T., Huang, X., Han, L., Wang, X., Cheng, H., Zhao, Y., Chen, Q., Chen, J., Cheng, H., Xiao, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.379164 · Cited by 208
“Our previous studies have shown that up-regulation of MFN2 in response to oxidative stress triggers the apoptotic death of vascular smooth muscle cells and cardiomyocytes, whereas down-regulation or dysregulation of MFN2 leads to vascular proliferative disorders (22, 23, 27, 28).”
BackgroundSelf-citationMitochondrial Dynamics in Cardiovascular Health and Disease
Ong, S.-B., Hall, A. R., & Hausenloy, D. J. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4777 · Cited by 207
“At the time of its initial discovery as a mammalian mitochondrial fusion protein in 2001, it had been independently discovered in muscle from Zucker obese rats (named mitochondrial assembly regulatory factor or MARF) (6), and in vascular smooth muscle cells of rats with genetic hypertension (named hyperplasia suppress…”
InfluentialMitochondrial dynamics and Ca2+ signaling
Szabadkai, G., Simoni, A. M., Bianchi, K., De Stefani, D., Leo, S., Wieckowski, M. R., & Rizzuto, R. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.002 · Cited by 204
Janer, A., Prudent, J., Paupe, V., Fahiminiya, S., Majewski, J., Sgarioto, N., Des Rosiers, C., Forest, A., Lin, Z., Gingras, A., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506159 · Cited by 202
“Indeed, there are several reports of direct links between the GTPases that regulate morphology and signaling pathways including Notch (Kasahara et al, 2013), antiviral signaling (Castanier et al, 2010), and Ras (Chen et al, 2004).”
BackgroundMitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases
Whitaker, R. M., Corum, D., Beeson, C. C., & Schnellmann, R. G. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103155 · Cited by 200
Mitofusin 2 Triggers Vascular Smooth Muscle Cell Apoptosis via Mitochondrial Death Pathway
Guo, X., Chen, K.-H., Guo, Y., Liao, H., Tang, J., & Xiao, R.-P. (2007) · Circulation Research · doi:10.1161/circresaha.107.157644 · Cited by 200
“This conclusion is corroborated by the following lines of evidence: (1) overexpression of rMfn-2 markedly inhibits both basal and mitogenic stimulus–induced Akt activation; (2) under the same experimental conditions, the rMfn-2–mediated inhibition of Akt activation is much greater and occurs earlier than the inhibitio…”
Self-citationMitophagy, Mitochondrial Dynamics, and Homeostasis in Cardiovascular Aging
Wu, N. N., Zhang, Y., & Ren, J. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9825061 · Cited by 197
Mitochondrial fusion proteins: Dual regulators of morphology and metabolism
Zorzano, A., Liesa, M., Sebastián, D., Segalés, J., & Palacín, M. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2010.01.002 · Cited by 196
Marzetti, E., Csiszar, A., Dutta, D., Balagopal, G., Calvani, R., & Leeuwenburgh, C. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00936.2012 · Cited by 196
PGC1α-mediated Mitofusin-2 Deficiency in Female Rats and Humans with Pulmonary Arterial Hypertension
Ryan, J. J., Marsboom, G., Fang, Y.-H., Toth, P. T., Morrow, E., Luo, N., Piao, L., Hong, Z., Ericson, K., Zhang, H. J., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201209-1687oc · Cited by 195
Cigarette smoke-induced mitochondrial fragmentation and dysfunction in human airway smooth muscle
Aravamudan, B., Kiel, A., Freeman, M., Delmotte, P., Thompson, M., Vassallo, R., Sieck, G. C., Pabelick, C. M., & Prakash, Y. S. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00155.2013 · Cited by 192
Mitofusin-2 Is a Major Determinant of Oxidative Stress-mediated Heart Muscle Cell Apoptosis
Shen, T., Zheng, M., Cao, C., Chen, C., Tang, J., Zhang, W., Cheng, H., Chen, K.-H., & Xiao, R.-P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702657200 · Cited by 184
Self-citationSarcoplasmic reticulum–mitochondria communication in cardiovascular pathophysiology
Lopez-Crisosto, C., Pennanen, C., Vasquez-Trincado, C., Morales, P. E., Bravo-Sagua, R., Quest, A. F. G., Chiong, M., & Lavandero, S. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.23 · Cited by 178
Salabei, J. K., & Hill, B. G. (2013) · Redox Biology · doi:10.1016/j.redox.2013.10.011 · Cited by 169
“These results are in harmony also with previous studies showing that overexpression of Mfn2 inhibits VSMC proliferation [30].”
ResultChen, K.-H., Dasgupta, A., Lin, J., Potus, F., Bonnet, S., Iremonger, J., Fu, J., Mewburn, J., Wu, D., Dunham-Snary, K., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031258 · Cited by 165
Self-citationKissing and nanotunneling mediate intermitochondrial communication in the heart
Huang, X., Sun, L., Ji, S., Zhao, T., Zhang, W., Xu, J., Zhang, J., Wang, Y., Wang, X., Franzini-Armstrong, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300741110 · Cited by 164
Mitochondrial dynamics in pulmonary arterial hypertension
Ryan, J., Dasgupta, A., Huston, J., Chen, K.-H., & Archer, S. L. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1263-5 · Cited by 163
“Indeed, MFN2 was initially referred to as hyperplasia suppressor gene when it was cloned because of its antiproliferative effect [76].”
BackgroundInfluentialSelf-citationMitofusin 2: A Mitochondria-Shaping Protein with Signaling Roles Beyond Fusion
de Brito, O. M., & Scorrano, L. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1934 · Cited by 152
“MFN2 expression levels have been linked to vascular proliferative diseases: in hyperproliferating vascular smooth muscle cells, MFN2 expression is downregulated (15).”
(De)constructing Mitochondria: What For?
Dimmer, K. S., & Scorrano, L. (2006) · Physiology · doi:10.1152/physiol.00010.2006 · Cited by 152
de Brito, O. M., & Scorrano, L. (2009) · Mitochondrion · doi:10.1016/j.mito.2009.02.005 · Cited by 152
“The resulting mutant lacks aminoacids 77-91, corresponding to the p21Ras-binding domain of MFN2 (Chen et al., 2004).”
BackgroundInfluentialMitochondrial Dysfunction in Atherosclerosis
Peng, W., Cai, G., Xia, Y., Chen, J., Wu, P., Wang, Z., Li, G., & Wei, D. (2019) · DNA and Cell Biology · doi:10.1089/dna.2018.4552 · Cited by 166
“Chen et al. (2004) showed that Mfn-2 was decreased in hyper-proliferative VSMCs from atherosclerotic plaques or balloon lesions, and Mfn2 overexpression blocked the proliferation of neointimal VSMCs after balloon injury and prevented restenosis caused by balloon injury.”
Role of mitofusin 2 mutations in the physiopathology of Charcot–Marie–Tooth disease type 2A
Cartoni, R., & Martinou, J. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.003 · Cited by 171
“The Ras domain has been found to be required to maintain a normal ER morphology in MEFs.”
BackgroundInfluentialMFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling
Xu, K., Chen, G., Li, X., Wu, X., Chang, Z., Xu, J., Zhu, Y. T., Yin, P., Liang, X., & Dong, L. (2017) · Scientific Reports · doi:10.1038/srep41718 · Cited by 154
Mitochondria-Endoplasmic Reticulum Contacts in Reactive Astrocytes Promote Vascular Remodeling
Gӧbel, J., Engelhardt, E., Pelzer, P., Sakthivelu, V., Jahn, H. M., Jevtic, M., Folz-Donahue, K., Kukat, C., Schauss, A., Frese, C. K., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.005 · Cited by 148
Araya, L. E., Soni, I. V., Hardy, J. A., & Julien, O. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00456 · Cited by 156
Oxidative Stress in Ischemic Heart Disease
Kibel, A., Lukinac, A. M., Dambic, V., Juric, I., & Selthofer-Relatic, K. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6627144 · Cited by 144
“Mitofusini 1 (Mfn1) is an important GTPase that regulates VMSC proliferation and apoptosis and acts as an important endogenous inhibitor of VSMC proliferation by inhibiting the Ras-Raf-ERK 1/2 pathway during the atherosclerotic process [103, 104].”
BackgroundOng, S., Kalkhoran, S. B., Cabrera-Fuentes, H. A., & Hausenloy, D. J. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.04.056 · Cited by 151
The many shapes of mitochondrial death
Cereghetti, G. M., & Scorrano, L. (2006) · Oncogene · doi:10.1038/sj.onc.1209605 · Cited by 166
“Moreover, levels of Mfn2 regulate oxidative metabolism in muscle mitochondria and are diminished in obese patients as well as in a rat model of type II diabetes (Bach et al., 2003); levels of Mfn2 can also control neointimal proliferation in models of hypertension (Chen et al., 2004).”
BackgroundMitochondrial metabolism and the control of vascular smooth muscle cell proliferation
Chiong, M., Cartes-Saavedra, B., Norambuena‐Soto, I., Mondaca‐Ruff, D., Morales, P. E., García-Miguel, M., & Mellado, R. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00072 · Cited by 153
“In spontaneously hypertensive or atherosclerosis-prone rat VSMC, Mfn-2 levels were diminished (Chen et al., 2004), while overexpression of Mfn2 reduced VSMC proliferation and sensitized to H2O2induced apoptosis (Guo et al., 2007a,b).”
BackgroundInfluentialLopez-Bigas, N., Kisiel, T. A., DeWaal, D. C., Holmes, K. B., Volkert, T. L., Gupta, S., Love, J., Murray, H. L., Young, R. A., & Benevolenskaya, E. V. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.08.004 · Cited by 136
“Downregulation of RBP2 triggers both processes that may contribute to ‘‘flat’’ cell phenotype in SAOS-2 cells, consistent with data on rat MFN2 protein, which functions as a cell proliferation suppressor (Chen et al., 2004).”
BackgroundDown-regulation of mitofusin-2 expression in cardiac hypertrophy in vitro and in vivo
Lu, F. Y., Moore, X., Gao, X., Dart, A. M., Lim, Y. L., & Du, X. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.04.003 · Cited by 135
From Structure to Function: Mitochondrial Morphology, Motion and Shaping in Vascular Smooth Muscle
McCarron, J. G., Wilson, C., Sandison, M. E., Olson, M. L., Girkin, J. M., Saunter, C. D., & Chalmers, S. (2013) · Journal of Vascular Research · doi:10.1159/000353883 · Cited by 164
Yap1 Protein Regulates Vascular Smooth Muscle Cell Phenotypic Switch by Interaction with Myocardin
Xie, C., Guo, Y., Zhu, T., Zhang, J., Ma, P. X., & Chen, Y. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.329268 · Cited by 134
“VSMC Proliferation Assays—Cell proliferation was determined by growth curves of VSMCs derived from cell counting as described before (36).”
MethodSelf-citationMitochondrial fission‐fusion as an emerging key regulator of cell proliferation and differentiation
Mitra, K. (2013) · BioEssays · doi:10.1002/bies.201300011 · Cited by 133
“It remains to be tested whether inhibition of cell proliferation in vascular smooth muscle cells with overexpression of MFN2 [56] or reduction of DRP1 activity [57] could be due to p53 activation, whichmay also lead to cell cycle exit or senescence”
BackgroundThe changing shape of mitochondrial apoptosis
Wasilewski, M., & Scorrano, L. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.03.007 · Cited by 131
Wang, W., Xie, Q., Zhou, X., Yao, J., Zhu, X., Huang, P., Zhang, L., Wei, J., Xie, H., Zhou, L., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.025 · Cited by 135
Potenza, N., Vecchione, C., Notte, A., Rienzo, A. D., Rosica, A., Bauer, L., Affuso, A., Felice, M. D., Russo, T., Poulet, R., et al. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400397 · Cited by 145
Mitochondria-Associated Endoplasmic Reticulum Membranes in Cardiovascular Diseases
Gao, P., Yan, Z., & Zhu, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.604240 · Cited by 141
Huang, P., Galloway, C. A., & Yoon, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020655 · Cited by 124
“In addition, genetic dysregulation of the mitochondrial fusion protein Mfn2 has been associated with vascular proliferative disorders [23], as well as obesity and type 2 diabetes [24].”
BackgroundMitochondrial dynamics as a bridge between mitochondrial dysfunction and insulin resistance
Zorzano, A., Liesa, M., & Palacín, M. (2009) · Archives of Physiology and Biochemistry · doi:10.1080/13813450802676335 · Cited by 124
“At the same time, in 2003 and 2004 it was demonstrated an impaired Mfn2 expression in skeletal muscle of obese and/or type 2 diabetic patients and in vascular smooth muscle cells of hypertense rats (Bach et al., 2003, 2005; Chen et al., 2004).”
BackgroundRogers, M. A., Maldonado, N., Hutcheson, J. D., Goettsch, C., Goto, S., Yamada, I., Faits, T., Sesaki, H., Aikawa, M., & Aïkawa, E. (2017) · Circulation Research · doi:10.1161/circresaha.116.310293 · Cited by 130
The Balance of MFN2 and OPA1 in Mitochondrial Dynamics, Cellular Homeostasis, and Disease
Zanfardino, P., Amati, A., Perrone, M., & Petruzzella, V. (2025) · Biomolecules · doi:10.3390/biom15030433 · Cited by 144
“Additionally, MFN2 possesses a unique N-terminal P21 Ras-binding domain, distinguishing it functionally from its homolog MFN1 [18].”
Adaniya, S. M., O-Uchi, J., Cypress, M. W., Kusakari, Y., & Jhun, B. S. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00523.2018 · Cited by 118
“Similarly, on the basis of in silico consensus sequence analysis, several groups showed that Mfn2 can be phosphorylated by PKA at Ser442 in noncardiac cells (24, 212), which is the same site as the predicted PINK1-dependent phosphorylation site on Mfn2 in CMs (Table 4 and Fig.”
BackgroundMitochondrial Dynamics in Adult Cardiomyocytes and Heart Diseases
Li, A., Gao, M., Jiang, W., Qin, Y. H., & Gong, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.584800 · Cited by 131
“80% in 10-month-old spontaneously hypertensive rats, as compared to the control group, while the ratios of heart weight to body weight and atrial natriuretic peptide (ANP) expression increased markedly (Chen et al., 2004; Fang et al., 2007).”
BackgroundRole of mitofusin 2 (Mfn2) in controlling cellular proliferation
Chen, K., Dasgupta, A., Ding, J., Indig, F. E., Ghosh, P., & Longo, D. L. (2014) · The FASEB Journal · doi:10.1096/fj.13-230037 · Cited by 112
“Apart from its major involvement in mitochondrial fusion, dysfunction of this gene is also associated with a variety of pathological conditions, including Charcot-Marie-Tooth (CMT) disease type 2A (3, 4), diabetes mellitus type 2 (5, 6), obesity (7), atherosclerosis, and hypertension (8, 9), suggesting the diverse fun…”
BackgroundMethodInfluentialSelf-citationWang, D., Uhrín, P., Mocan, A., Waltenberger, B., Breuss, J. M., Tewari, D., Mihaly‐Bison, J., Huminiecki, Ł., Starzyński, R. R., Tzvetkov, N. T., et al. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.006 · Cited by 116
Identification of a Novel Mitochondrial Complex Containing Mitofusin 2 and Stomatin-like Protein 2
Hájek, P., Chomyn, A., & Attardi, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608168200 · Cited by 111
Pokharel, M. D., Flores, A. G., Marciano, D. P., Franco, M. C., Fineman, J. R., Aggarwal, S., Wang, T., & Black, S. M. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103049 · Cited by 136
“Moreover, Mfn2 inhibits smooth muscle cell proliferation [8,271].”
BackgroundMitochondrial Fusion Proteins and Human Diseases
Ranieri, M., Brajkovic, S., Riboldi, G., Ronchi, D., Rizzo, F., Bresolin, N., Corti, S., & Comi, G. P. (2013) · Neurology Research International · doi:10.1155/2013/293893 · Cited by 110
Keeping mitochondria in shape: a matter of life and death
Scorrano, L. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12135 · Cited by 132
Lugus, J. J., Ngoh, G. A., Bachschmid, M. M., & Walsh, K. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.07.023 · Cited by 108
“Opa1-mediated fusion is dependent upon Mfn1 but not Mfn2 [22], and a Ras-binding domain located on the Nterminus of Mfn2 but not Mfn1 is thought to confer a growthsuppressive effect by sequestering Ras [42].”
HIV-1 Vpr Triggers Mitochondrial Destruction by Impairing Mfn2-Mediated ER-Mitochondria Interaction
Huang, K. C., Chiang, S., Lin, T., Chiou, S.-H., & Chow, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033657 · Cited by 116
“Other than functioning in mitochondrial fusion, Mfn2 can act as a cell proliferation suppressor to inhibit cell cycle transition from the G1 to S phase [34,35].”
BackgroundRegulation of mitochondrial morphology and function by O-GlcNAcylation in neonatal cardiac myocytes
Makino, A., Suarez, J., Gawlowski, T., Han, W., Wang, H., Scott, B. T., & Dillmann, W. H. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00437.2010 · Cited by 105
“are related with neuropathy (7, 8, 11, 13, 49) and there is a report showing a change in DRP1 protein expression by hyperglycemia (25) and another study indicating a close relationship between MFN2”
BackgroundSmall G Proteins in the Cardiovascular System: Physiological and Pathological Aspects
Loirand, G., Sauzeau, V., & Pacaud, P. (2013) · Physiological Reviews · doi:10.1152/physrev.00021.2012 · Cited by 103
Mitofusins deficiency elicits mitochondrial metabolic reprogramming to pluripotency
Son, M. J., Kwon, Y., Son, M.-Y., Seol, B., Choi, H.-S., Ryu, S.-W., Choi, C., & Cho, Y. S. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.43 · Cited by 104
“of homology with Mfn2) directly bind Ras and Raf, resulting in the inhibition of cell proliferation via sequestration of Ras-RafERK signaling.(17,18) Under our experimental conditions, we observed a dramatic increase in the levels of phosphorylated Raf, ERK, PI3K, Akt, and mTOR proteins in the reprogramming intermedia…”
BackgroundJežek, P., & Plecitá‐Hlavatá, L. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.02.014 · Cited by 114
Mitochondrial-Shaping Proteins in Cardiac Health and Disease – the Long and the Short of It!
Ong, S.-B., Kalkhoran, S. B., Hernández-Reséndiz, S., Samangouei, P., Ong, S.-G., & Hausenloy, D. J. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6710-1 · Cited by 100
“Engineered mutant Mfn2 expressed from birth which cannot be PINK1-phosphorylated on Thr111 and Ser442 as required for Mfn2-Parkin binding disrupts developmental perinatal transformation of cardiac metabolism [153].”
BackgroundMitochondrial Dynamics and Mitophagy in Cardiometabolic Disease
Lin, J., Duan, J., Wang, Q., Xu, S., Zhou, S., & Yao, K. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.917135 · Cited by 115
“(147) found that MFN2 was significantly reduced in hyperproliferative VSMCs of AS plaques or balloon lesions, and that increasing MFN2 prevented neointimal VSMCs proliferation after balloon injury and prevented restenosis caused by balloon injury.”
BackgroundLipskaia, L., del Monte, F., Capiod, T., Yacoubi, S., Hadri, L., Hours, M. C., Hajjar, R. J., & Lompré, A. (2005) · Circulation Research · doi:10.1161/01.res.0000180663.42594.aa · Cited by 110
STAT3 Protein Regulates Vascular Smooth Muscle Cell Phenotypic Switch by Interaction with Myocardin
Liao, X., Wang, N., Zhao, D., Zheng, D., Zheng, L., Xing, W., Ma, W., Bao, L., Dong, J., & Zhang, T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.630111 · Cited by 104
“VSMC Proliferation Assays—Cell proliferation was determined by the growth curves of VSMCs; cell counting was performed as described previously (30).”
MethodThe role of mitochondrial dynamics in human cancers.
Ma, Y., Wang, L., & Jia, R. (2020) · PubMed Central · Cited by 138
Anti-Tumor Effects of Mfn2 in Gastric Cancer
Zhang, G., Jin, H., Lin, X.-K., Chen, C., Liu, X., Zhang, Q., & Yu, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140713005 · Cited by 103
“The p21 (Ras) signature motif in the N-terminal region of Mfn2 is important for its regulation of the cell cycle.”
BackgroundInfluentialKnowlton, A. A., Chen, L., & Malik, Z. A. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000432861.55968.a6 · Cited by 103
“Mfn2, which is also known as hyperplasia suppressor gene, inhibits vascular smooth muscle cell proliferation in vitro and in a rat model of carotid injury.(40) Mfn2 is decreased in diabetes and obesity.”
Background
Metadata
- Authors
- Chen, K.-H., Guo, X., Ma, D., Guo, Y., Li, Q., Yang, D., Li, P., Qiu, X., Wen, S., Xiao, R.-P., & Tang, J.
- Affiliations
- National Institutes of Health (US)
- Peking University (CN)
- Corresponding author
- Xiao, Rui-Ping
- ORCID
- Venue
- Nature Cell Biology
- Published
- 2004-08-22
- Volume
- 6
- Issue
- 9
- Pages
- 872-883
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2104828119
- Cited by
- 370
- References
- 50
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 6 · 2023: 12 · 2022: 26 · 2021: 22 · 2020: 18 · 2019: 19 · 2018: 22 · 2017: 18 · 2016: 21 · 2015: 24 · 2014: 20 · 2013: 32 · 2012: 26
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Surgery › Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Keywords
- HSG, mitofusin 2, vascular smooth muscle cell proliferation, restenosis, intimal hyperplasia, atherosclerosis, ERK/MAPK signalling, cell cycle arrest, mitochondrial targeting, mitochondrial fusion, spontaneously hypertensive rats, balloon injury, ApoE-deficient mice
- MeSH terms
- Animals, Arteriosclerosis, Cardiovascular Diseases, Cell Division, Gene Expression Regulation, Humans, Membrane Proteins, Molecular Sequence Data, Muscle, Smooth, Vascular, Oncogene Protein p21(ras), Mice, Knockout, GTP Phosphohydrolases, MAP Kinase Signaling System, Coronary Restenosis, Mitochondrial Proteins, Myocytes, Smooth Muscle, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.